Brii Biosciences Enters a Licensing Deal with Joincare Pharmaceutical for BRII-693 to Treat Bacterial Infections

Brii Biosciences has entered into a license & technology transfer agreement with Joincare to develop & commercialize BRII-693 in the Greater China regionAs per the deal, Joincare will handle development, regulatory activities & commercialization of BRII-693 in Greater China in exchange for an upfront payment as well as development & commercial milestones, with net…

ByRidhi RastogiJuly 4, 2025

NEWS

Brii Bio Signs an Agreement with VBI Vaccines to Acquire BRII-179’s IP Rights

Shots:Brii Bio & VBI Vaccines have signed an asset purchase agreement to acquire IP rights of BRII-179 (novel recombinant protein-based HBV immunotx., expressing Pre-S1, Pre-S2 & S HBV surface antigens) As per the terms, Brii will acquire BRII-179’s patents, know-how & associated materials for $18M (eliminating all future milestones & royalty obligations). Prior…

BySenior EditorJanuary 1, 2025

Brii Biosciences Enters a Licensing Deal with Joincare Pharmaceutical for BRII-693 to Treat Bacterial Infections

Brii Bio Signs an Agreement with VBI Vaccines to Acquire BRII-179’s IP Rights

Contact US

OUR INFORMATION

FOLLOW US